<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A"><gtr:id>9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A</gtr:id><gtr:name>Guy's and St Thomas' NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Westminster Bridge Road</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 7EH</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B8E83F1-1755-4FA2-8767-31A3E9591295"><gtr:id>4B8E83F1-1755-4FA2-8767-31A3E9591295</gtr:id><gtr:name>Laboratory of the Government Chemist (LGC) Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C07D0FC4-D8D1-4731-9DF0-20960D10572C"><gtr:id>C07D0FC4-D8D1-4731-9DF0-20960D10572C</gtr:id><gtr:name>Roquette Pharma</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8D6B540D-3EA5-47AE-A05F-180C21CC06CC"><gtr:id>8D6B540D-3EA5-47AE-A05F-180C21CC06CC</gtr:id><gtr:name>Thermo Fisher Scientific</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>National Heart and Lung Institute</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A"><gtr:id>9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A</gtr:id><gtr:name>Guy's and St Thomas' NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Westminster Bridge Road</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 7EH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B8E83F1-1755-4FA2-8767-31A3E9591295"><gtr:id>4B8E83F1-1755-4FA2-8767-31A3E9591295</gtr:id><gtr:name>Laboratory of the Government Chemist (LGC) Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C07D0FC4-D8D1-4731-9DF0-20960D10572C"><gtr:id>C07D0FC4-D8D1-4731-9DF0-20960D10572C</gtr:id><gtr:name>Roquette Pharma</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8D6B540D-3EA5-47AE-A05F-180C21CC06CC"><gtr:id>8D6B540D-3EA5-47AE-A05F-180C21CC06CC</gtr:id><gtr:name>Thermo Fisher Scientific</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/BDA78D1E-1BC3-45B7-AD4E-D0BEF05B9980"><gtr:id>BDA78D1E-1BC3-45B7-AD4E-D0BEF05B9980</gtr:id><gtr:firstName>Maria</gtr:firstName><gtr:otherNames>Gabriela</gtr:otherNames><gtr:surname>Belvisi</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/45775202-D89D-4CD4-BB6F-3C582BD938BC"><gtr:id>45775202-D89D-4CD4-BB6F-3C582BD938BC</gtr:id><gtr:firstName>Kazuhiro</gtr:firstName><gtr:surname>Ito</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9CF3D997-EE83-49A2-8AEA-28F2259C6D0A"><gtr:id>9CF3D997-EE83-49A2-8AEA-28F2259C6D0A</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Birrell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0502019"><gtr:id>A0CB30F2-9B0F-40EF-B3C6-6055ABF778A3</gtr:id><gtr:title>Effect of cyclodextrin on sensory nerve activity and the cough reflex in man: a novel anti-tussive therapy?</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0502019</gtr:grantReference><gtr:abstractText>Cough is a reflex mechanism that helps clear foreign material and secretions from the airways. However, it may also be the first and most persistent symptom of many inflammatory airways diseases, including, asthma, COPD, post viral infections, pulmonary fibrosis and bronchiectasis. Chronic cough can also be present when a cause can not be identified. At present there are no effective treatments for this condition. Therefore, the identification of new drugs for the treatment of chronic cough will be of immense benefit and will greatly enhance the quality of life of many patients and sufferers. The reflex action of coughing is initiated when sensory nerves in the airway are activated. Our research looks into whether agents which prevent the sensory nerves in the airway from being activated, will also inhibit the cough reflex. This project in particular looks at cyclodextrin as a possible agent. Previous pre-clinical studies have demonstrated the inhibitory effects of cyclodextrin in preventing cough. This project seeks to take this work further and to test the inhibitory activity of cyclodextrins on the cough reflex in man.</gtr:abstractText><gtr:technicalSummary>Cough is an important defense mechanism that helps clear excessive secretions and foreign material from the airways. However, it also presents as the first and most persistent symptom of many inflammatory airways diseases, including asthma, COPD, post viral infections, pulmonary fibrosis and bronchiectasis. Chronic cough can also be idiopathic in nature. To date, the only effective treatments for cough are opioids which have central and peripheral side effects. Therefore, the identification of novel therapeutic targets for the treatment of chronic cough will be of immense therapeutic benefit and will greatly enhance the quality of life of patients. The cough reflex is initiated by activation of airway sensory afferent nerves. We hypothesize that agents that inhibit sensory nerve activity will also inhibit the cough reflex. In this proposal we describe pre-clinical data demonstrating the anti-tussive activity of cyclodextrins both in vitro on sensory nerve function and in vivo in a guinea-pig cough model. The aim of this proposal is to test the anti-tussive activity of this molecule in man and to investigate the possible mechanism of action.</gtr:technicalSummary><gtr:fund><gtr:end>2009-10-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-03-31</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>349220</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Roquette Pharma</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Provision of substance</gtr:description><gtr:id>70B36D50-A92C-4E32-9AAC-AFF9F3696E1E</gtr:id><gtr:impact>Issues are still ongoing regarding analysis of the stability of cyclodextrin which we hope will be resolved soon so as we can progress to the clinical trial and publication of data.</gtr:impact><gtr:outcomeId>082A6B34D2A-1</gtr:outcomeId><gtr:partnerContribution>Guided us with their technical expertise in the formulation of cyclodextrin for use in this trial. Provision of cyclodextrin and technical support in formulation of the IV solution for use in the trial.</gtr:partnerContribution><gtr:piContribution>Liaising with the company to provide cyclodextrin for human use.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy's and St Thomas' NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Formulation of cyclodextrin and stability analysis for intravenous use in patients.</gtr:description><gtr:id>9412CB88-7F33-4AA9-9B98-8AF0C78908B6</gtr:id><gtr:impact>Issues are still ongoing regarding analysis of the stability of cyclodextrin which we hope will be resolved soon so as we can progress to the clinical trial and publication of the data.</gtr:impact><gtr:outcomeId>8259FF2EF8B-1</gtr:outcomeId><gtr:partnerContribution>Formulation of cyclodextrin and stability analysis for intravenous use in patients.</gtr:partnerContribution><gtr:piContribution>Laising with the company to provide data needed for use of cyclodextrin in man.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Thermo Fisher Scientific</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Dionex</gtr:department><gtr:description>Technical support for analysis of cyclodextrin</gtr:description><gtr:id>6FE4CE5B-9591-45EF-B526-CF6CE9E593FD</gtr:id><gtr:impact>Issues are still ongoing regarding analysis of the stability of cyclodextrin which we hope will be resolved soon so as we can progress to the clinical trial and publication of the data.</gtr:impact><gtr:outcomeId>4A93BE67B22-1</gtr:outcomeId><gtr:partnerContribution>Technical support for analysis of cyclodextrin.</gtr:partnerContribution><gtr:piContribution>Laising with the company to provide data needed for use of cyclodextrin in man.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Laboratory of the Government Chemist (LGC) Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPLC analysis of cyclodextrin solution</gtr:description><gtr:id>0B268F7D-AB13-4A1D-83DC-A397EA4D9060</gtr:id><gtr:impact>Issues are still ongoing regarding analysis of the stability of cyclodextrin which we hope will be resolved soon so as we can progress to the clinical trial and publication of the data.</gtr:impact><gtr:outcomeId>97269588735-1</gtr:outcomeId><gtr:partnerContribution>HPLC analysis of cyclodextrin solution</gtr:partnerContribution><gtr:piContribution>Laising with the company to provide data needed for use of cyclodextrin in man.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Pharmacokinetic analysis of cyclodextrin in the blood from patients in phase 1 of the proposed clinical trial.</gtr:description><gtr:id>8250EAE0-7EE1-4F53-A061-170FD12C62A3</gtr:id><gtr:impact>Issues are still ongoing regarding analysis of the stability of cyclodextrin which we hope will be resolved soon so as we can progress to the clinical trial and publication of the data.</gtr:impact><gtr:outcomeId>6C31E83BAD6-1</gtr:outcomeId><gtr:partnerContribution>Pharmacokinetic analysis of cyclodextrin in the blood of patients from the phase 1 clinical trial.</gtr:partnerContribution><gtr:piContribution>Laising with the company to provide data needed for use of cyclodextrin in man.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>550000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>9CE2CE2C-1C32-4368-AA89-40259AFE1DF3</gtr:id><gtr:outcomeId>67589DF6F8E0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ERS Guidelines for the assessment of cough. Eur Respir J. 2007 Jun;29(6):1256-76</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:guidelineTitle>Cough guidelines</gtr:guidelineTitle><gtr:id>E46D33F0-1C60-499A-9D71-F5FDE7FEF97F</gtr:id><gtr:impact>Participation in creating the above guidelines.; Influencing training of practitioners</gtr:impact><gtr:outcomeId>664FC521932</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have characterised and validated the use of the KoKo dosimeter to assess the cough response in man. This is in keeping with published ERS guidelines.</gtr:description><gtr:id>A05D37CD-AAEC-4914-B984-1A32F8E41FAA</gtr:id><gtr:impact>Provides standardised analysis of the cough reponse between interntaional research sites.</gtr:impact><gtr:outcomeId>41B3DF610C2</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Validation of a dosimeter used in the tussive challenge</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>862F7482-1A98-453F-BF07-5F853D8BD93F</gtr:id><gtr:title>ERS guidelines on the assessment of cough.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/113faf4ab829dc948e8c948bccee6f7a"><gtr:id>113faf4ab829dc948e8c948bccee6f7a</gtr:id><gtr:otherNames>Morice AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>06CCA826D6D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E77B02F2-901F-4F93-B6C8-4F70FA0CDFC3</gtr:id><gtr:title>Prostaglandin E2 mediates cough via the EP3 receptor: implications for future disease therapy.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf94e702df2683997992c62be33df36b"><gtr:id>bf94e702df2683997992c62be33df36b</gtr:id><gtr:otherNames>Maher SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>02F87B7D6A3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20747882-7419-4DA5-B286-A9EDCDCA292D</gtr:id><gtr:title>EP4 receptor as a new target for bronchodilator therapy.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35ed95dd227d373240e59c417dc003ae"><gtr:id>35ed95dd227d373240e59c417dc003ae</gtr:id><gtr:otherNames>Buckley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>bcexwHBqxfW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2B8060E-0257-424E-8EF6-96F448B8798E</gtr:id><gtr:title>Beta(2)-agonists block tussive responses in guinea pigs via an atypical cAMP-dependent pathway.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b126f1cfae83695c2f8c38cf8f18020f"><gtr:id>b126f1cfae83695c2f8c38cf8f18020f</gtr:id><gtr:otherNames>Freund-Michel VC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>oM9ywoN5Zfi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>115FADA9-E066-4D65-B22B-FDB68E318EBD</gtr:id><gtr:title>TRPA1 agonists evoke coughing in guinea pig and human volunteers.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3b657577dc9fc228f1740c838d26434"><gtr:id>c3b657577dc9fc228f1740c838d26434</gtr:id><gtr:otherNames>Birrell MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>71E15C4609C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63158A25-9E6D-4469-970B-91D364A91B71</gtr:id><gtr:title>Inhibitory activity of the novel CB2 receptor agonist, GW833972A, on guinea-pig and human sensory nerve function in the airways.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5c62caf0f822d853f7fdf984d2f220f"><gtr:id>b5c62caf0f822d853f7fdf984d2f220f</gtr:id><gtr:otherNames>Belvisi MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>A0358921F87</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67B9A6AF-ACBC-47FB-832B-AA2BD38BE09D</gtr:id><gtr:title>Preclinical assessment of novel therapeutics on the cough reflex: cannabinoid agonists as potential antitussives.</gtr:title><gtr:parentPublicationTitle>Lung</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5c62caf0f822d853f7fdf984d2f220f"><gtr:id>b5c62caf0f822d853f7fdf984d2f220f</gtr:id><gtr:otherNames>Belvisi MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0341-2040</gtr:issn><gtr:outcomeId>C1B86369619</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0502019</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>